Cell & Gene Therapy Bioanalytical Testing Services Market

How Fast Is the Cell & Gene Therapy Bioanalytical Testing Services Market Growing?

The global cell & gene therapy bioanalytical testing services market size is expected to be valued at US$ 0.633 billion in 2026 and projected to reach US$ 1.041 billion by 2033, growing at a CAGR of 7.4% between 2026 and 2033.

Between 2020 and 2025, the market grew at a CAGR of about 9.6%, as a wave of CAR-T and AAV gene therapy programs entered clinical trials and sponsors outsourced complex assays. Three factors now support growth: a steady flow of new approvals, strict regulatory demands for potency assays, vector biodistribution, and long-term follow-up, and the lack of in-house bioanalytical capacity at most biotechs. The market is shifting toward GMP-validated qPCR and ddPCR assays, flow cytometry, and immunogenicity testing delivered by specialized contract research organizations across all development stages.

• By Test Type: Bioavailability & Bioequivalence held 29.4% share in 2026, while Pharmacokinetics is projected to expand at an 8.6% CAGR through 2033, driven by cellular kinetics and vector persistence studies required in clinical programs.
• By Stage of Development: Non-clinical held 54.6% share in 2026, while Clinical is projected to expand at an 8.1% CAGR through 2033, driven by more programs entering Phase 2 and pivotal trials.
• By Product Type: Cell Therapy held 47.2% share in 2026, while Gene-Modified Cell Therapy is projected to expand at an 8.9% CAGR through 2033, driven by CAR-T and TCR programs that need transgene and persistence testing.
• By Indication: Oncology held 51.8% share in 2026, while Rare Diseases are projected to expand at a 9.0% CAGR through 2033, driven by AAV gene therapies for inherited disorders.
• By Region: North America held 46.5% share in 2026, while Asia Pacific is projected to expand at a 9.4% CAGR through 2033, driven by fast-growing CAR-T pipelines in China and new cell therapy hubs in India.

Two drivers carry the strongest influence on cell and gene therapy bioanalytical testing demand during the forecast period.

New Approvals and a Deep Pipeline Are Driving Cell & Gene Therapy Bioanalytical Testing

A steady stream of approvals and a deep clinical pipeline are the main drivers of cell and gene therapy bioanalytical testing demand. Each program needs specialized assays to measure how cells expand, how long vectors persist, and how the immune system responds.

The evidence is recent regulatory activity. In 2024, the U.S. Food and Drug Administration approved several first-of-their-kind products, including Tecelra, the first engineered T-cell receptor therapy, Aucatzyl, a CAR-T therapy for leukemia, Kebilidi, a gene therapy for a rare neurological disorder, and Ryoncil, the first mesenchymal stromal cell therapy. Each approval followed years of bioanalytical studies across non-clinical and clinical stages. Hundreds of programs remain in trials worldwide, and many sponsors outsource testing because building qPCR and ddPCR assays and flow cytometry capabilities in-house is costly.

Strict Regulatory Requirements Raise Demand for Cell & Gene Therapy Bioanalytical Testing

Strict regulatory requirements raise the volume and complexity of cell and gene therapy bioanalytical testing. Regulators expect sponsors to prove that products are potent, consistent, and safe over long periods after a single treatment.

The mechanism is detailed guidance from regulators. The U.S. Food and Drug Administration recommends long-term follow-up of up to 15 years for some gene therapy products, which requires repeated persistence and safety testing. Agency guidance on potency assurance asks sponsors to develop assays that reflect the product's mechanism of action. Vector biodistribution and shedding studies show where vectors travel in the body and whether they are released in fluids. Immunogenicity testing measures antibodies against AAV capsids and transgene products. The European Medicines Agency has similar expectations for advanced therapy medicinal products, adding further testing for global programs.

Two restraints limit how quickly the market can grow.

Assay Complexity and Limited Standardization Slow Cell & Gene Therapy Bioanalytical Testing

Assay complexity and limited standardization slow delivery of cell and gene therapy bioanalytical testing. Each product often needs custom methods, which take months to develop and validate before clinical samples can be tested.

The underlying causes are biological variability and evolving guidance. Living cells and viral vectors behave differently from small molecules or antibodies, so standard pharmacokinetic methods do not apply directly. Potency assays must reflect complex mechanisms such as killing tumor cells or expressing a gene. qPCR and ddPCR assays require careful primer design and validation for each transgene. Flow cytometry panels need specialized reagents and trained scientists. Few shared reference standards exist, making comparisons across laboratories and studies difficult. These factors raise costs, extend timelines, and limit how quickly service providers can scale capacity to meet rising sponsor demand.

Funding Volatility and Program Cancellations Weigh on Cell & Gene Therapy Bioanalytical Testing

Funding volatility and program cancellations weigh on demand for cell and gene therapy bioanalytical testing. When biotech funding tightens, sponsors delay or cut clinical programs, reducing outsourced testing work and causing abrupt contract cancellations.

The specific causes are high development costs, commercial challenges, and investor caution. Some approved therapies have struggled with slow uptake because of very high prices, complex administration, and reimbursement hurdles. In February 2025, Pfizer said it would stop development and commercialization of its hemophilia B gene therapy Beqvez, citing limited patient and physician interest. Such decisions make investors more cautious about the sector. Smaller biotechs with limited cash may pause programs, narrow pipelines, or seek partners before moving into costly late-stage trials. Service providers then face uneven demand, idle laboratory capacity, and pressure on scientific staffing.

GMP-Validated AAV and Vector Assays Open a Specialized Revenue Pool in Cell & Gene Therapy Bioanalytical Testing

GMP-validated assays for AAV and other viral vectors create a specialized, high-value revenue pool. Sponsors need reliable, reproducible methods to quantify vectors, measure capsid content, and track biodistribution, often under strict quality standards.

Contract research organizations with deep molecular biology expertise can capture this demand. In February 2025, Labcorp Drug Development launched validated AAV vector quantification and characterization assays under GMP conditions. In January 2025, ICON announced a partnership with a gene therapy company to provide centralized bioanalytical testing across multi-center trials. Eurofins has invested in ddPCR, analytical ultracentrifugation, and electron microscopy for viral vector testing. Gene therapy developers and their contract manufacturing partners are the main customers. Providers offering validated, ready-to-use methods can shorten timelines and win long-term, multi-study contracts.

Asia Pacific Cell Therapy Hubs Create a Fast-Growing Revenue Pool for Bioanalytical Testing

New cell and gene therapy hubs in Asia Pacific create a fast-growing revenue pool for bioanalytical testing services. China has one of the world's largest CAR-T pipelines, and India is building local capacity for affordable cell therapies.

Global and regional service providers that build laboratories in the region can capture this demand. In February 2024, Miltenyi Biotec opened a Cell & Gene Therapy Center of Excellence in Hyderabad. In 2025, Bharat Biotech announced a US$ 75 million cell and gene therapy research and manufacturing facility in Hyderabad. Pharmaron and other Chinese providers are expanding biologics and advanced therapy testing. Local biotechs, academic centers, and global sponsors running trials in the region are the main customers. Lower costs and fast patient enrollment attract international programs.

• By Test Type: Bioavailability & Bioequivalence Lead While Pharmacokinetics Grows Fastest

Bioavailability & Bioequivalence held 29.4% share in 2026. These studies show how much of a product reaches its target and compare manufacturing processes or new production sites. Sponsors use them when scaling manufacturing or making process changes, which are frequent in cell and gene therapy development.

Pharmacokinetics is the fastest-growing test type, expanding at an 8.6% CAGR through 2033. For cell therapies, pharmacokinetics means measuring how cells expand, persist, and decline in patients, often with qPCR and ddPCR assays and flow cytometry. For gene therapies, it covers vector persistence and transgene expression. Regulators expect these data in clinical trials and long-term follow-up. Immunogenicity, potency, and biodistribution testing also grow. For the market, pharmacokinetic demand creates repeated testing across many patient time points, which increases sample volumes.

• By Stage of Development: Non-clinical Leads While Clinical Grows Fastest

Non-clinical held 54.6% share in 2026. Before first-in-human trials, sponsors must complete animal biodistribution, toxicology, and potency studies. Many programs are still in early development, so non-clinical work makes up the largest share of testing.

Clinical is the fastest-growing stage, expanding at an 8.1% CAGR through 2033. More programs are moving into Phase 2 and pivotal trials, where large numbers of patient samples must be tested under validated methods. Long-term follow-up studies add years of testing after treatment. Multi-center trials require centralized laboratories and harmonized assays. For the market, clinical growth shifts revenue toward high-volume, GMP- and GCLP-compliant testing, which favors large contract research organizations with global laboratory networks and strong sample logistics.

• By Product Type: Cell Therapy Leads While Gene-Modified Cell Therapy Grows Fastest

Cell Therapy held 47.2% share in 2026. This category includes stem cell, mesenchymal stromal cell, and immune cell therapies that require cell counting, viability, potency, and identity testing. Approvals such as Ryoncil show the growing role of non-genetically modified cell products.

Gene-Modified Cell Therapy is the fastest-growing product type, expanding at an 8.9% CAGR through 2033. CAR-T and TCR therapies combine living cells with genetic modification, so they need both cell-based assays and vector or transgene testing. New approvals such as Tecelra and Aucatzyl and many pipeline programs for solid tumors and autoimmune diseases add demand. Gene therapies, including AAV and lentiviral products, are also significant. For the market, gene-modified cell therapies create some of the most complex and highest-value testing work.

• By Indication: Oncology Leads While Rare Diseases Grow Fastest

Oncology held 51.8% share in 2026. Most approved and pipeline cell therapies target cancers such as leukemia, lymphoma, multiple myeloma, and some solid tumors. Oncology trials require extensive pharmacokinetic, immunogenicity, and safety testing.

Rare Diseases are the fastest-growing indication, expanding at a 9.0% CAGR through 2033. AAV gene therapy and other genetic medicines target inherited disorders such as hemophilia, muscular dystrophy, and rare neurological diseases. Approvals such as Kebilidi show progress in this area. Rare disease programs need highly sensitive assays for long-term vector persistence and immune responses. Autoimmune and cardiovascular indications are also emerging. For the market, rare disease growth adds steady demand for long-term follow-up testing, even though patient numbers per trial are small.

• Which Region Is Leading the Cell & Gene Therapy Bioanalytical Testing Services Market?

North America is leading the cell & gene therapy bioanalytical testing services market with a 46.5% share in 2026. The United States has the largest number of cell and gene therapy developers, clinical trials, and approvals. Major providers such as Labcorp, Charles River Laboratories, PPD, BioAgilytix, and KCAS Bioanalytical Services operate specialized laboratories in the region. The U.S. Food and Drug Administration sets detailed expectations for potency, persistence, and long-term follow-up. Venture capital and academic research support a deep pipeline. Canada adds activity in cell therapy research. One change shaping the region is consolidation as providers expand assay menus.

• Europe Strengthens Advanced Therapy Testing in Cell & Gene Therapy Bioanalytical Services

Europe is a major market supported by strong academic research and regulatory frameworks for advanced therapy medicinal products. The United Kingdom, Germany, France, Spain, and the Netherlands host many developers and clinical trials. The United Kingdom is noted for rapid growth, supported by the Cell and Gene Therapy Catapult. Eurofins, SGS, and other providers operate laboratories across the region. The European Medicines Agency sets strict requirements for potency and safety testing. Funding constraints and complex, multi-country trial approvals can slow programs. One opportunity is cross-border multi-center trials needing centralized testing.

• Which Region Is Growing Fastest in the Cell & Gene Therapy Bioanalytical Testing Services Market?

Asia Pacific is growing fastest in the cell & gene therapy bioanalytical testing services market at a 9.4% CAGR through 2033. China has one of the world's largest CAR-T pipelines and many local developers. India is developing affordable cell therapies and new research hubs, including facilities by Miltenyi Biotec and Bharat Biotech in Hyderabad. Japan offers a conditional approval pathway for regenerative medicine products. South Korea and Australia support clinical trials. Lower costs and fast patient enrollment attract global sponsors. Varied national regulations and data transfer rules remain a barrier. One opportunity is regional GLP and GCLP laboratory networks.

• Latin America Builds Clinical Trial Capacity in Cell & Gene Therapy Bioanalytical Testing

Latin America is an emerging region where clinical trial participation drives demand for bioanalytical testing. Brazil, Argentina, and Mexico host trials for oncology and rare disease therapies because of large, diverse patient populations. Leading academic hospitals in Brazil are developing locally produced CAR-T therapies. Key barriers include limited specialized laboratories, complex biological sample export rules, and currency volatility. Many samples are still shipped to central laboratories in North America or Europe, which adds time and risk to sample integrity. One opportunity is building regional laboratories that meet international standards, reducing shipping time and costs for sponsors.

• Middle East & Africa Invests in Biotechnology for Cell & Gene Therapy Bioanalytical Testing

Middle East & Africa is an early-stage region with growing government investment in biotechnology. Saudi Arabia's Vision 2030 initiative supported more than SAR 1.5 billion in biotechnology research and development by October 2025. The United Arab Emirates and Qatar are building research centers and genomics programs. High rates of inherited disorders in the Gulf create interest in gene therapies. In Africa, South Africa has limited but growing clinical research capacity at academic medical centers. Key barriers include few specialized laboratories, scarce bioanalytical expertise, and limited trial volumes. One opportunity is partnerships with global providers to build local testing capacity.

The cell & gene therapy bioanalytical testing services market is moderately concentrated. Large global contract research organizations such as Labcorp, Charles River Laboratories, Thermo Fisher Scientific through PPD, IQVIA, ICON, and Syneos Health hold strong positions. Focused specialists such as BioAgilytix, KCAS Bioanalytical Services, Prolytix, and Avance Biosciences focus on complex assays. Eurofins, SGS, and Pharmaron add global laboratory capacity.

Providers compete on scientific expertise, assay validation speed, regulatory track record, capacity, and data quality. Proven experience with qPCR and ddPCR assays, flow cytometry, potency testing, and immunogenicity testing is critical for winning programs. Sponsors increasingly prefer partners offering integrated services from non-clinical to clinical stages, which reduces method transfer risk between laboratories.

Strategic moves show how competition is changing. Labcorp Drug Development launched GMP-validated AAV vector assays in February 2025. ICON formed a centralized bioanalytical testing partnership with a gene therapy developer in January 2025. Eurofins expanded cell and gene therapy laboratories in Lancaster and Columbia in the United States. Avance Biosciences consolidated sequencing platforms and talent in July 2025. Together, these moves show providers building specialized capacity, validated methods, and global laboratory footprints.

Three main themes now shape vendor strategy. First, companies are investing in molecular, cell-based, and sequencing technologies. Second, they are expanding laboratories in Asia Pacific and Europe to support global trials. Third, they are offering validated, platform assays that reduce development time for sponsors working on similar vectors.

Recent Industry Developments

• February 2025: Labcorp Drug Development launched validated AAV vector quantification and characterization assays under GMP – shortens assay development for gene therapy sponsors.
• January 2025: ICON announced a centralized bioanalytical testing partnership with a gene therapy company – supports harmonized testing across multi-center trials.
• February 2024: Miltenyi Biotec opened a Cell & Gene Therapy Center of Excellence in Hyderabad – expands advanced therapy capability in India.

• Labcorp
• Charles River Laboratories
• Thermo Fisher Scientific (PPD)
• BioAgilytix
• Eurofins Scientific
• IQVIA
• ICON
• Syneos Health
• KCAS Bioanalytical Services
• Prolytix
• Pharmaron
• SGS

Test Type

• Bioavailability & Bioequivalence
• Pharmacokinetics
• Pharmacodynamics
• Immunogenicity
• Biodistribution & Shedding
• Potency

Stage of Development

• Non-clinical
• Clinical

Product Type

• Cell Therapy
• Gene Therapy
• Gene-Modified Cell Therapy

Indication

• Oncology
• Rare Diseases
• Neurology
• Autoimmune Diseases
• Others

Regions

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa